The Committee for Medicinal Products for Human Use (CHMP) recommends updating the product information of the leukaemia medicine Iclusig^® (ponatinib) to include new warnings in order to minimise the risk of a higher rate of blood clots.

For more information visit:

European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots